Page 2 - Life Edit News Today

Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies fo...

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global

By Dominic Chopping Novo Nordisk said Wednesday that it has established a collaboration deal with Life Edit Therapeutics to discover and develop gene-editing therapies. The Danish... | May 24, 2023

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on... | May 24, 2023

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Here are the details.

Operator: Good day and thank you for standing by. Welcome to Modernas First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.

First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating

MRNA earnings call for the period ending March 31, 2023.